Cybin Inc. to Present at Jefferies Global Healthcare Conference in London

Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN), a Phase 3 clinical-stage neuropsychiatry company developing proprietary drug discovery platforms and delivery systems to transform mental healthcare, announced that George Tziras, chief business officer, will present at the Jefferies Global Healthcare Conference scheduled for November 17–20, 2025, in London, United Kingdom. This presentation represents a significant milestone for the company as it continues to advance its pipeline of novel mental health treatments and seeks to attract institutional investment in the emerging field of psychedelic-based therapeutics.

The company's participation in this prestigious global healthcare conference underscores the growing recognition of psychedelic-derived compounds as potential breakthrough treatments for mental health disorders. Cybin is currently developing CYB003, a proprietary deuterated psilocin analog, in Phase 3 studies for the adjunctive treatment of major depressive disorder. This investigational treatment has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration, indicating its potential to demonstrate substantial improvement over existing therapies for serious conditions.

Additionally, Cybin is advancing CYB004, a proprietary deuterated N, N-dimethyltryptamine molecule in a Phase 2 study for generalized anxiety disorder. The company maintains a research pipeline of investigational, 5-HT-receptor focused compounds, positioning itself at the forefront of neuropsychiatry innovation. The presentation at Jefferies Global Healthcare Conference provides an opportunity for the company to showcase its promising class-leading data and progress in developing next-generation treatment options that could address the large unmet need for people suffering from mental health conditions worldwide.

The selection to present at this high-profile conference reflects the increasing institutional validation of psychedelic medicine as a legitimate and promising approach to mental healthcare. As mental health disorders continue to represent a significant global health burden, with current treatments often providing inadequate relief for many patients, Cybin's work in developing novel drugs that provide effective and durable results could potentially transform the mental health treatment landscape. The conference presentation represents a crucial step in building awareness and support for the company's mission to revolutionize mental healthcare through innovative therapeutic approaches.

For investors and stakeholders seeking additional information about Cybin's developments, the company maintains updated information available through its corporate communications channels. The latest news and updates relating to CYBN are accessible through the company's dedicated newsroom at https://ibn.fm/CYBN, providing ongoing transparency about the company's progress in developing potentially transformative mental health treatments.